Wyden Hails Roadmap for Medicare Prescription Drug Price Negotiation

Webp adobestock 226444001
Adobe Stock

Wyden Hails Roadmap for Medicare Prescription Drug Price Negotiation

The following press release was published by the United States Senate Committee on Finance Chairman's News on Jan. 11. It is reproduced in full below.

Washington, D.C. - Senate Finance Committee Chair Ron Wyden, D-Ore., today hailed an announcement by the Centers for Medicare and Medicaid Services (CMS) outlining the timeline and mechanisms for Medicare drug price negotiation policies as it goes into effect this year:

“Today’s announcement is a critical step towards unshackling Medicare and delivering on the promise of drug pricing fairness," Wyden said. “The Inflation Reduction Act finally empowers Medicare to negotiate the price of prescription drugs. These historic provisions, along with reforms that are already in effect to cap insulin costs and ensure free access to vaccines, will reduce costs for millions of seniors across the country. I look forward to working with Administrator Brooks-LaSure and the entire Biden administration as these critical policies go into effect and deliver lower drug prices to American families."

More information on the announcement can be found here.

Source: US Senate Committee on Finance Chairman's News

More News